Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large

European Journal of Cancer

Volumn 49, Issue 11, 2013, Pages 2542-2554

  Friesen, Claudia ^a   Roscher, Mareike ^a   Hormann, Inis ^a   Leib, Oliver ^b   Marx, Sebastian ^b   Moreno, Josue ^b   Miltner, Erich ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Isotope Technologies Garching ITG   (Germany)

Author keywords

Acute myeloid leukaemia; Alpha emitter; Anti CD33 antibody; Bismuth 213; Cancer; Chemoresistance; Radioimmunotherapy; Radioresistance; Targeted alpha therapy

Indexed keywords

ANTIBODY; BISMUTH 213; CASPASE; CD33 ANTIBODY BI 213; PROTEIN BCL XL; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BCL-X PROTEIN; BISMUTH; CASPASES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; SIALIC ACID BINDING IG-LIKE LECTIN 3; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84879320732     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.008     Document Type: Article

References (42)

1. H.J. de Jonge, G. Huls, and E.S. de Bont Gene expression profiling in acute myeloid leukaemia Neth J Med 69 4 2011 167 176
2. L.N. Han, J. Zhou, J.J. Schuringa, and E. Vellenga Treatment strategies in acute myeloid leukemia Chin Med J (Engl) 124 9 2011 1409 1421
3. K. Stockerl-Goldstein, and K. Blume Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia E. Thomas, K. Blume, S. Forman, Hematopoietic cell transplantation 1999 Blackwell Science Oxford 823 834
4. K. Ogawa, S. Murayama, and M. Mori Predicting the tumor response to radiotherapy using microarray analysis (Review) Oncol Rep 18 5 2007 1243 1248
5. C. Friesen, S. Fulda, and K.M. Debatin Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells Leukemia 11 11 1997 1833 1841
6. S. Fulda Tumor resistance to apoptosis Int J Cancer 124 3 2009 511 515
7. J.C. Timmer, and G.S. Salvesen Caspase substrates Cell Death Differ 14 1 2007 66 72
8. R.G. Andrews, J.W. Singer, and I.D. Bernstein Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties J Exp Med 169 5 1989 1721 1731
9. P.A. Dinndorf, R.G. Andrews, D. Benjamin, D. Ridgway, L. Wolff, and I.D. Bernstein Expression of normal myeloid-associated antigens by acute leukemia cells Blood 67 4 1986 1048 1053
10. G. Leone, S. Sica, M.T. Voso, S. Rutella, and L. Pagano Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects Cardiovasc Hematol Agents Med Chem 4 1 2006 33 52
11. D.A. Scheinberg, M. Tanimoto, S. McKenzie, A. Strife, L.J. Old, and B.D. Clarkson Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia Leukemia 3 6 1989 440 445
12. A. Varki, and T. Angata Siglecs - the major subfamily of I-type lectins Glycobiology 16 1 2006 1R 27R
13. R.A. Larson, M. Boogaerts, and E. Estey Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) Leukemia 16 9 2002 1627 1636
14. J.G. Jurcic, T. DeBlasio, L. Dumont, T.-J. Yao, and D.A. Scheinberg Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia Clin Cancer Res 6 2 2000 372 380
15. E. Feldman, M. Kalaycio, and G. Weiner Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195 Leukemia 17 2 2003 314 318
16. A. Raza, J.G. Jurcic, and G.J. Roboz Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial Leuk Lymphoma 50 8 2009 1336 1344
17. T.L. Rosenblat, M.R. McDevitt, and D.A. Mulford Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia Clin Cancer Res 16 21 2010 5303 5311
18. C. Apostolidis, R. Molinet, J. McGinley, K. Abbas, J. Mollenbeck, and A. Morgenstern Cyclotron production of Ac-225 for targeted alpha therapy Appl Radiat Isot 62 3 2005 383 387
19. T.K. Nikula, M.J. Curcio, M.W. Brechbiel, O.A. Gansow, R.D. Finn, and D.A. Scheinberg A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies Nucl Med Biol 22 3 1995 387 390
20. T.K. Nikula, M.R. McDevitt, and R.D. Finn Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry J Nucl Med 40 1 1999 166 176
21. G. Sgouros, A.M. Ballangrud, and J.G. Jurcic Pharmacokinetics and dosimetry of an {alpha}-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia J Nucl Med 40 11 1999 1935 1946
22. M. Carbonari, M. Cibati, and M. Cherchi Detection and characterization of apoptotic peripheral blood lymphocytes in human immunodeficiency virus infection and cancer chemotherapy by a novel flow immunocytometric method Blood 83 5 1994 1268 1277
23. S. Fulda, H. Sieverts, C. Friesen, I. Herr, and K.M. Debatin The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells Cancer Res 57 17 1997 3823 3829
24. I. Nicoletti, G. Migliorati, M.C. Pagliacci, F. Grignani, and C. Riccardi A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J Immunol Methods 139 2 1991 271 279
25. C. Friesen, G. Glatting, and B. Koop Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells Cancer Res 67 5 2007 1950 1958
26. M. Roscher, I. Hormann, and O. Leib Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells Oncotarget 4 2 2013 218 230
27. T. Petrich, Z. Korkmaz, D. Krull, C. Fromke, G.J. Meyer, and W.H. Knapp In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin Eur J Nucl Med Mol Imaging 37 5 2010 851 861
28. J.L. Dearling, and R.B. Pedley Technological advances in radioimmunotherapy Clin Oncol (R Coll Radiol) 19 6 2007 457 469
29. G. Kroemer, L. Galluzzi, and P. Vandenabeele Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 Cell Death Differ 16 1 2009 3 11
30. A. Saraste, and K. Pulkki Morphologic and biochemical hallmarks of apoptosis Cardiovasc Res 45 3 2000 528 537
31. E.C. LaCasse, D.J. Mahoney, H.H. Cheung, S. Plenchette, S. Baird, and R.G. Korneluk IAP-targeted therapies for cancer Oncogene 27 48 2008 6252 6275
32. S. Cory, and J.M. Adams The Bcl2 family: regulators of the cellular life-or-death switch Nat Rev Cancer 2 9 2002 647 656
33. J.P. Bergmann, and D. Harris Radioresistance, chemoresistance, and apoptosis resistance Radiat Oncol 27 1997 47 57
34. L. Milas, U. Raju, Z. Liao, and J. Ajani Targeting molecular determinants of tumor chemo-radioresistance Semin Oncol 32 2005 78 81
35. J. Kotzerke, D. Bunjes, and D.A. Scheinberg Radioimmunoconjugates in acute leukemia treatment: the future is radiant Bone Marrow Transplant 36 12 2005 1021 1026
36. J.G. Jurcic, S.M. Larson, and G. Sgouros Targeted alpha particle immunotherapy for myeloid leukemia Blood 100 4 2002 1233 1239
37. D.A. Mulford, D.A. Scheinberg, and J.G. Jurcic The promise of targeted α-particle therapy J Nucl Med 46 1 2005 199 204
38. C. Friesen, A. Lubatschofski, J. Kotzerke, I. Buchmann, S.N. Reske, and K.M. Debatin Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells Eur J Nucl Med Mol Imaging 30 9 2003 1251 1261
39. P.C. Caron, J.G. Jurcic, and A.M. Scott A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity Blood 83 7 1994 1760 1768
40. M. Schuyler, K. Gott, V. Mapel, A. Cherne, and K.J. Nikula Experimental hypersensitivity pneumonitis: influence of Th2 bias Int J Exp Pathol 80 6 1999 335 348
41. P. Li, D. Nijhawan, and I. Budihardjo Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade Cell 91 1997 479 489
42. M.O. Hengartner The biochemistry of apoptosis Nature 407 6805 2000 770 776